期刊
CANADIAN JOURNAL OF GASTROENTEROLOGY
卷 25, 期 7, 页码 377-383出版社
PULSUS GROUP INC
DOI: 10.1155/2011/953975
关键词
Cannabinoid receptors; Colon cancer; Emesis; Inflammatory bowel disease; Irritable bowel syndrome; Rimonabant; THC
资金
- Austrian Science Fund (FWF) [P22771-B18]
- F Lanyar Foundation
- Crohn's and Colitis Foundation of Canada
- Austrian Science Fund (FWF) [P 22771] Funding Source: researchfish
- Austrian Science Fund (FWF) [P22771] Funding Source: Austrian Science Fund (FWF)
Many beneficial effects of herbal and synthetic cannabinoids on gut motility and inflammation have been demonstrated, suggesting a vast potential for these compounds in the treatment of gastrointestinal disorders. These effects are based on the so-called 'endocannabinoid system' (ECS), a cooperating network of molecules that regulate the metabolism of the body's own and of exogenously administered cannabinoids. The ECS in the gastrointestinal tract quickly responds to homeostatic disturbances by de novo synthesis of its components to maintain homeostasis, thereby offering many potential targets for pharmacological intervention. Of major therapeutic interest are nonpsychoactive cannabinoids or compounds that do not directly target cannabinoid receptors but still possess cannabinoid-like properties. Drugs that inhibit endocannabinoid degradation and raise the level of endocannabinoids are becoming increasingly promising alternative therapeutic tools to manipulate the ECS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据